You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 28, 2024

Details for New Drug Application (NDA): 204760


✉ Email this page to a colleague

« Back to Dashboard


NDA 204760 describes MOVANTIK, which is a drug marketed by Valinor and is included in one NDA. It is available from three suppliers. There are four patents protecting this drug and one Paragraph IV challenge. Additional details are available on the MOVANTIK profile page.

The generic ingredient in MOVANTIK is naloxegol oxalate. There are three drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the naloxegol oxalate profile page.
Summary for 204760
Tradename:MOVANTIK
Applicant:Valinor
Ingredient:naloxegol oxalate
Patents:4
Formulation / Manufacturing:see details
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for 204760
Generic Entry Date for 204760*:
Constraining patent/regulatory exclusivity:
Dosage:
TABLET;ORAL

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Pharmacology for NDA: 204760
Mechanism of ActionOpioid Antagonists
Suppliers and Packaging for NDA: 204760
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
MOVANTIK naloxegol oxalate TABLET;ORAL 204760 NDA Quality Care Products, LLC 55700-988 55700-988-30 30 TABLET, FILM COATED in 1 BOTTLE (55700-988-30)
MOVANTIK naloxegol oxalate TABLET;ORAL 204760 NDA RedHill Biopharma Ltd 57841-1300 57841-1300-1 30 TABLET, FILM COATED in 1 BOTTLE (57841-1300-1)

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrengthEQ 12.5MG BASE
Approval Date:Sep 16, 2014TE:RLD:Yes
Patent:⤷  Try a TrialPatent Expiration:Jun 29, 2024Product Flag?YSubstance Flag?Delist Request?
Patented Use:TREATMENT OF OPIOID-INDUCED CONSTIPATION
Patent:⤷  Try a TrialPatent Expiration:Sep 16, 2028Product Flag?YSubstance Flag?YDelist Request?
Patent:⤷  Try a TrialPatent Expiration:Dec 16, 2024Product Flag?Substance Flag?Delist Request?
Patented Use:TREATMENT OF OPIOID-INDUCED CONSTIPATION

Expired US Patents for NDA 204760

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Valinor MOVANTIK naloxegol oxalate TABLET;ORAL 204760-001 Sep 16, 2014 ⤷  Try a Trial ⤷  Try a Trial
Valinor MOVANTIK naloxegol oxalate TABLET;ORAL 204760-002 Sep 16, 2014 ⤷  Try a Trial ⤷  Try a Trial
Valinor MOVANTIK naloxegol oxalate TABLET;ORAL 204760-002 Sep 16, 2014 ⤷  Try a Trial ⤷  Try a Trial
Valinor MOVANTIK naloxegol oxalate TABLET;ORAL 204760-001 Sep 16, 2014 ⤷  Try a Trial ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.